
    
      Patients will be randomized 2:1 to receive either single agent OSI-906 (Arm A) or placebo
      (Arm B) and will be stratified according to prior systemic cytotoxic chemotherapy for ACC,
      and Eastern Cooperative Oncology Group (ECOG) performance status, and use of >= 1 oral
      antihyperglycemic therapy at randomization
    
  